Lung cancer screening program marketing: eligibility, shared decisions, harms and smoking data

A lung cancer screening program markets to people who feel well. The audience is adults with a long smoking history, current or former, and the message has to reach them without fear, without promises and without sending their smoking history to an ad platform. Who is eligible, and in whose words? What has to happen before the first scan? Can an ad say screening saves lives? What does a page owe readers about false positives? This guide covers what the U.S. Preventive Services Task Force (USPSTF), the Medicare national coverage determination, the National Cancer Institute and the federal advertising and privacy rules say, and how to turn that into pages, letters and ads.

Three related topics have their own guides and are not repeated here. Condition pages for a lung practice and the Medicare.gov coverage wording are covered in our guide to pulmonology and respiratory clinic marketing. Quit programs, quit claims and quitlines are covered in our guide to smoking and vaping cessation program marketing. Scan pricing, self-referral and radiation wording for imaging centers are covered in our guide to imaging center marketing. This guide covers what is specific to a lung cancer screening program.

What the USPSTF and the patient pages say about lung cancer screening

The USPSTF recommendation is the source a screening page should quote for who is at high risk, and the National Cancer Institute (NCI) patient summary is the source a careful patient reads. They say:

• The USPSTF Lung Cancer: Screening recommendation (published March 9, 2021) gives a grade B to annual screening with low-dose computed tomography (CT) for “adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years”.
• It defines one pack-year as smoking an average of one pack a day for a year, and it tells clinicians to engage in shared decision-making about screening with people who meet the criteria.
• It says screening should stop once a person has not smoked for 15 years, or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.
• It names the harms: false-positive results and incidental findings that can lead to more testing and treatment, the anxiety of living with a lung lesion that may be cancer, overdiagnosis, and radiation exposure.
• The NCI Lung Cancer Screening summary (updated May 24, 2024) says screening with low-dose CT has been shown to decrease the risk of dying from lung cancer in heavy smokers, and that screening with chest x-rays or sputum cytology does not decrease that risk.
• It lists the risks: finding lung cancer may not improve health or help a person live longer, false-negative and false-positive results can occur, a false-positive result can cause anxiety and lead to more tests such as a biopsy, which also have risks, and CT scans expose the chest to radiation.
• The MedlinePlus Lung Cancer topic page (last updated May 5, 2025) gathers the NCI and other federal pages a patient can read next.

Two points from these pages shape the marketing. First, screening is for a defined group of people without symptoms, so a page has to say who it is for and send anyone with symptoms to a regular visit instead. Second, the federal pages put the harms next to the benefit, and a program page that shows only the benefit says less than the sources it relies on.

Eligibility in the source’s words, and the gap between them

The USPSTF criteria and the Medicare criteria are not the same. The CMS National Coverage Determination 210.14 (effective February 10, 2022) covers the scan for people aged 50 to 77 with no signs or symptoms of lung cancer, at least 20 pack-years, who currently smoke or quit within the last 15 years, and who have an order for the scan. The USPSTF upper age is 80. Private plans set their own rules, and your billing team can confirm them plan by plan.

That gap is where ads go wrong. An ad that says “covered for adults 50 to 80” is wrong for a Medicare patient aged 78. Quote each source with its name and date, keep the clinical recommendation and the coverage rule in separate sentences, and tell readers to check their own coverage. The full Medicare.gov wording is in our pulmonology guide.

Phrases that need rewriting:

• “Free lung scan for smokers”. Say who the USPSTF recommendation covers, and that cost depends on the plan.
• “Medicare covers it for everyone over 50”. Quote the NCD conditions, including the upper age, the pack-years and the order.
• “No referral needed”. Medicare coverage requires an order, and the first scan follows a decision visit.
• “Worried about a cough? Get screened”. Screening is for people without symptoms. Tell readers with symptoms to book a regular visit.

The shared decision visit is part of the program

NCD 210.14 says that before the first scan a Medicare patient must have a counseling and shared decision-making visit, documented in the record, that includes: a check of eligibility; shared decision-making with one or more decision aids; counseling on keeping to annual screening, the impact of other conditions and the ability or willingness to have diagnosis and treatment; and counseling on staying quit for former smokers, or on quitting for current smokers, with information about cessation programs where appropriate. The NCD also sets rules for the reading radiologist and the imaging facility.

For marketing, that means the booking path starts with a visit, not a scan. A page can say what the visit covers, that a decision aid will be used, and that the patient can decide not to be screened. A landing page that sells the scan alone and skips the visit sets up a patient who arrives expecting a scan that day. If your program has a nurse navigator or a coordinator, say what that person does, in plain words.

Saves lives, catches it early and other claims

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices, services or cosmetics. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that an advertiser is responsible for the claims a reasonable reader takes away, including implied ones.

The evidence for lung cancer screening is about a group: low-dose CT has been shown to decrease the risk of dying from lung cancer in heavy smokers. It does not say that a scan will save the reader’s life, and the NCI lists that finding lung cancer may not help a person live longer. Use the source’s words, name the source, and keep the claim at the level of the group.

Phrases that need rewriting:

• “Catch it early, save your life”. Quote the NCI: screening with low-dose CT has been shown to decrease the risk of dying from lung cancer in heavy smokers.
• “A clear scan means you are cancer-free”. The NCI says false-negative results can occur. Say what the scan looks for and that results are discussed at a follow-up.
• “Zero radiation worries” or “perfectly safe”. The USPSTF and the NCI list radiation exposure as a harm. Say it is a low-dose scan and that the visit covers the risks.
• “Screening is better than quitting”. The USPSTF and the NCD put cessation counseling into the program. Write about both together.
• “Results in minutes, no follow-up needed”. The USPSTF describes follow-up imaging for findings. Say how results and follow-up are handled.

False positives, follow-up and fear

A program page earns trust by saying what happens after an abnormal result. Write it the way the sources do: a scan can show something that turns out not to be cancer, a follow-up scan may be advised, and a biopsy may be advised in certain cases, with its own risks. Name who calls the patient with results and how fast the office aims to call, if that is a promise the office keeps. Avoid images and copy built on fear of dying; the audience already knows the stakes, and fear-based copy sits badly next to a page that also has to describe harms.

A screening page is also read by people who have symptoms now. Add a short line for them: if you have a cough that does not go away, chest pain, coughing up blood or trouble breathing, book a regular visit instead of a screening; if you have sudden severe chest pain or severe trouble breathing, call 911.

Smoking history is health information

A screening intake form asks for age, pack-years and quit date. Where the program sits in a covered entity, that is protected health information, and so is the fact that a person used an eligibility quiz and booked. Keep the quiz answers and the booking out of tracking pixels and ad platform tools unless a written agreement covers them; our guide to HIPAA marketing rules covers the detail.

Ads have a second limit. The Google Ads personalized advertising policy restricts targeting based on health conditions, including health status. Target by place, age range where allowed and search terms, and do not build an audience from patients’ smoking status.

Outreach letters to the practice’s own patients raise a different question. 45 CFR 164.501 defines marketing and lists exceptions, including certain communications for the treatment of the individual. Whether a letter to patients who smoke about screening is a treatment communication or marketing depends on who sends it, what it says and whether anyone pays for it; ask your privacy officer and counsel before the first mailing. Letters that do not need an authorization still go only to patients the clinician would invite, and they never name the condition on the envelope.

The same smoking history list feeds another federal screening recommendation with its own groups. Our guide to abdominal aortic aneurysm screening outreach covers the one-time ultrasound for men aged 65 to 75 who have ever smoked, the Medicare rule and the recall wording.

Patient stories

A former smoker who had a nodule found and treated makes a strong story, and the story is one person’s result. Under 16 CFR 255.2, an ad that shows one person’s result on a key attribute is likely to be read as what others will generally achieve, unless the practice has substantiation for that or clearly and conspicuously discloses what people can generally expect. Where the practice is a covered entity, a story used to market the program needs a signed authorization under 45 CFR 164.508. Our guide to testimonials covers the full rules. Pair the story with the harms section, not in place of it.

Illustration: two ads for the same screening program

Illustration: an ad reads “Smoker? Catch lung cancer early and save your life. Free scan, no referral needed, results in minutes. Medicare covers everyone over 50.” It promises an individual result, calls the scan free without saying for whom, skips the order and the decision visit, and misstates the Medicare conditions.

Illustration: a second ad for the same program reads “Aged 50 to 80 and a long-time smoker, now or in the past? The USPSTF recommends a yearly low-dose CT lung scan for adults who meet its criteria. [Practice name] starts with a visit to talk through benefits and risks, including false positives, and help with quitting. Check your plan for coverage.” It quotes the USPSTF group, names the visit and the harms, links the program to quitting and leaves coverage to the plan.

Checklist before a screening campaign goes live

• Eligibility is quoted from the USPSTF and the NCD by name and date, in separate sentences.
• No ad says Medicare covers ages or groups the NCD does not.
• The booking path starts with the decision visit and says what it covers.
• The page lists the harms the USPSTF and the NCI name, and says how results and follow-up are handled.
• No page or ad says the scan will save a life, rule out cancer or carry no risk.
• People with symptoms are told to book a regular visit, with the 911 line for severe symptoms.
• Quiz answers, pack-years and bookings stay out of pixels and ad audiences.
• Outreach letters were reviewed under 45 CFR 164.501, and each story has a signed authorization.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses, including pulmonology and imaging practices that run screening programs. For a lung cancer screening program, that means program pages that quote the USPSTF and Medicare rules with links and dates, a booking path that starts with the decision visit, ads without life-saving promises, and eligibility forms that keep smoking history away from tracking tools. We do not decide who is screened or how care is delivered; your clinicians, your counsel and your state boards do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• USPSTF: Lung Cancer: Screening (published March 9, 2021)
• CMS: NCD 210.14 Lung Cancer Screening with Low Dose Computed Tomography (effective February 10, 2022)
• National Cancer Institute: Lung Cancer Screening (PDQ), Patient Version (updated May 24, 2024)
• MedlinePlus: Lung Cancer (last updated May 5, 2025)
• 15 U.S.C. 45: Unfair methods of competition unlawful
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• 45 CFR 164.501: Definitions
• 45 CFR 164.508: Uses and disclosures for which an authorization is required
• 16 CFR 255.2: Consumer endorsements
• Google Ads: Personalized advertising policy

More in Physician specialty marketing